Skip to main content
Top
Published in: Current Oncology Reports 3/2024

06-02-2024 | Lung Cancer | Review

Geographical Disparities in Lung Cancer in Canada: A Review

Author: Jamileh Yousefi

Published in: Current Oncology Reports | Issue 3/2024

Login to get access

Abstract

Purpose of Review

The eastern provinces of Canada exhibit a heightened prevalence and mortality rate of lung cancer compared to their western counterparts. While established risk factors for lung cancer exist in Canada, there remains ambiguity regarding the underlying provincial and territorial trends. This review aims to identify and analyze potential contributors to healthcare inequality, guiding policymakers towards a strategic and sustainable approach at the provincial level.

Recent Findings

Existing studies emphasize the significant roles played by socio-economic and environmental factors in influencing lung cancer disparities across Canadian provinces. However, a noticeable research gap persists, particularly in systematically examining the factors that amplify geographical disparities in lung cancer incidence and mortality rates within Canada.

Summary

This review underscores the disparities in lung cancer prevalence and mortality rates between eastern and western Canadian provinces. While socio-economic and environmental factors have been identified as influential, there is an evident need for further research to comprehensively understand and address the underlying contributors to these geographical discrepancies.
Footnotes
1
It should be noted that estimates for Quebec were not included due to a different projection approach, which renders those rates incomparable with the others.
 
Literature
1.••
go back to reference CCS, “Canadian cancer statistics: A 2020 special report on lung cancer,” Canada Cancer Society Technical Report, 2020. The “Canadian Cancer Statistics (CCS)” offers a detailed analysis of cancer trends, regional disparities, prevalence, and outcomes in Canada, synthesizing data from diverse sources to present insights on incidence, mortality, survival rates, and specific risk factors within the Canadian context. CCS, “Canadian cancer statistics: A 2020 special report on lung cancer,” Canada Cancer Society Technical Report, 2020. The “Canadian Cancer Statistics (CCS)” offers a detailed analysis of cancer trends, regional disparities, prevalence, and outcomes in Canada, synthesizing data from diverse sources to present insights on incidence, mortality, survival rates, and specific risk factors within the Canadian context.
3.••
go back to reference CCS, “Canadian cancer statistics 2021,” Canada Cancer Society Technical Report, 2021. The report provides comprehensive insights into the regional disparities, cancer trends, prevalence, and outcomes of cancer in Canada. Published consistently, this authoritative source integrates data from various outlets to deeply analyze cancer incidence, mortality, survival rates, and distinct risk factors pertinent to Canada. CCS, “Canadian cancer statistics 2021,” Canada Cancer Society Technical Report, 2021. The report provides comprehensive insights into the regional disparities, cancer trends, prevalence, and outcomes of cancer in Canada. Published consistently, this authoritative source integrates data from various outlets to deeply analyze cancer incidence, mortality, survival rates, and distinct risk factors pertinent to Canada.
4.
go back to reference Lee S. Risk factors for lung cancer, Technical report. Canadian Cancer Society; 2019. Lee S. Risk factors for lung cancer, Technical report. Canadian Cancer Society; 2019.
5.•
go back to reference Brenner DR, Weir HK, Demer AA, Ellison LF, Louzado C. Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199–205. https://doi.org/10.1503/cmaj.191292. The paper presents projected estimates related to cancer incidence, prevalence, mortality, and other relevant outcomes in Canada for the year 2020CrossRefPubMedPubMedCentral Brenner DR, Weir HK, Demer AA, Ellison LF, Louzado C. Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199–205. https://​doi.​org/​10.​1503/​cmaj.​191292. The paper presents projected estimates related to cancer incidence, prevalence, mortality, and other relevant outcomes in Canada for the year 2020CrossRefPubMedPubMedCentral
7.
go back to reference Canada S. Canadian cancer statistics: a 2020 special report on lung cancer, Technical report. Statistics Canada; 2020a. Canada S. Canadian cancer statistics: a 2020 special report on lung cancer, Technical report. Statistics Canada; 2020a.
42.•
go back to reference Slavik C, Demers PA, Tamburic L, McLeod C. Do patterns of past asbestos use and production reflect current geographic variations of cancer risk?: mesothelioma in Ontario and British Columbia, Canada. Cancer Causes Control. 2023;34(4):1–12. https://doi.org/10.1007/s10552-023-01672-4. This study explores the complex interplay between environmental factors and disparities, investigating how different environmental elements may influence or worsen variations in health outcomes.CrossRef Slavik C, Demers PA, Tamburic L, McLeod C. Do patterns of past asbestos use and production reflect current geographic variations of cancer risk?: mesothelioma in Ontario and British Columbia, Canada. Cancer Causes Control. 2023;34(4):1–12. https://​doi.​org/​10.​1007/​s10552-023-01672-4. This study explores the complex interplay between environmental factors and disparities, investigating how different environmental elements may influence or worsen variations in health outcomes.CrossRef
Metadata
Title
Geographical Disparities in Lung Cancer in Canada: A Review
Author
Jamileh Yousefi
Publication date
06-02-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 3/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01499-5

Other articles of this Issue 3/2024

Current Oncology Reports 3/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine